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Abstract 
 
This paper illustrates the application of mobile and 
wireless technologies for estimating the severity of 
Parkinson Disease symptoms, and performing a 
personalized drug administration to PD patients.  The 
measurements of patient finger pressures on the screen 
of a smart phone, translated into analogue voltage and 
digital bits, are taken by an Android App. The 
computations performed through Fast Fourier 
Transformations (FFT) and Reaction and Movement 
time, enable the calculation of the severity of the PD 
symptoms, which results in an appropriate drug 
administration for that patient, at the moment when the 
measurement of patient finger pressures is taken. The 
novelty of this research is twofold. It allows a high level 
of personalization in PD treatment and uses modern 
technologies to bring new solutions in the field of drug 
administration to PD patients. 
 
 
1. Introduction  
 
The problem of drug administration for patients 
suffering from Parkinson’s Disease (PD) has been 
known for decades and it has remained unresolved for  
many reasons.  Firstly, successful treatments of PD 
symptoms depend heavily on a particular patient and 
his/her manifestation of PD symptoms, which is often 
associated with the individual experience a patient may 
have throughout the day.  This means that we should 
personalize PD drug administration, in order to alleviate 
PD symptoms a patient may have at a particular 
moment. However, the personalization of medicine is 
still in its infancy.  Its research currently focuses more 
on genome sequencing in order to learn how to group 
patients based on risk of disease, or response to therapy, 
or use diagnostic tests or techniques for each patient [1].  
Secondly, we expect modern healthcare delivery to be 
supported by smart phones and numerous Apps we run 
on them. PD patients expect and possibly require, a new 
generation of hardware and software solutions in order 
to address their most urgent problem, which is 
personalized drug administration. Therefore in the 
second decade of the 21st century we have an 
opportunity to look at new ways of resolving the 
problem of optimal treatments of PD symptoms using 
new technologies, which may bring new solutions to old 
problems. If we focus solely on the PD drug 
administration, then we should find a method of 
(a) collecting information about PD symptoms a 
patient may have at any moment throughout the day 
(b) advising the patient on the best possible drug 
administration at that moment when the information is 
collected. 
Therefore, PD drug administration will vary from 
one moment to another throughout the day, because PD 
symptoms change.  We should create a synergy of 
hardware and software solutions for performing (a) and 
(b), which enables the manipulation of sensor generated 
data, as the result of the measurements of the severity of 
PD symptoms.  They are essential for appropriate drug 
administration.  Creating an App which administers PD 
drugs, runs on patient smart phones, at the time when 
the measurement of the severity of PD symptoms is 
taken, would be the ultimate answer expected by PD 
patients and healthcare professionals. 
This paper is organized as follows. In the next 
section we describe related work, and in section 3 we 
give a background of this research and explain the 
problems of PD drug administration.  In section 4 we 
introduce prerequisite for developing 
• ParMes device, attached to a patient smart phone 
which can measure the severity of PD symptoms,  
• ParMesApp, an Android App, which takes these 
measurements and administers drugs accordingly. 
These prerequisite include the way PD symptoms are 
estimated and drug administration calculated.  In section 
5 we explain the development of ParMes and 
ParMesApp, and evaluate our solution in the 
Conclusion.  
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2. Related Work 
 
At the time of writing this paper, we could not find 
any published work, which either personalizes PD drug 
administration through the measurement of the severity 
of PD symptoms, or offers a Software Architectural 
(SA) model for an App, which can advise on the best 
possible drug administration for a particular patient.  
Therefore we look at research in the field of remote 
patient monitoring and assisted living.  One of the best 
sources, which compiles projects funded by the EU, is 
available at [2]. They focus on e-health [3] which 
changes the way we deliver health services and create 
modern healthcare environments. However, in [2] the 
authors divide e-health into comfort and security, 
rehabilitation and chronic disease telemonitoring. Our 
work should belong to the latter, because any persistent 
data generated within ParMesApp can be remotely 
accessed by any other e-health system and healthcare 
professionals.  The comparative study from [2] pushes 
forward the problems, which have not been resolved yet, 
such as security in, impact of cognitive science on, and 
the existence of universal e-health systems. 
The rapid changes and advances of mobile and 
wireless technologies, which have seriously impacted 
our everyday lives, have also infiltrated in healthcare 
[4,5,6,7]. We have witnessed the proliferation of 
wearable medical systems which have been paving the 
way towards pervasive and personalized healthcare 
[8,9,10,11,12,13]. 
PD has also attracted the attention of various 
research groups in the domain of tele-monitoring and e-
health.  There are numerous reports and peer reviewed 
papers which range from focusing on the optimization 
of symptomatic therapy for PD patients [14], techniques 
for diagnosing and monitoring PD patients [15] and 
projects which focus on wireless body area networks 
[16] to accurate telemonitoring of PD patients through 
speech tests [17],  and medical devices which can be 
used in the managing and understanding degenerative 
diseases. 
 In terms of addressing the optimisation of PD 
treatment, we can find various approaches which range 
from the Tauberian approach [18],  decision support 
tools for optimal PD drug administration as in [19], to 
“patient diaries”, deep brain stimulation, and combining 
them with measuring/assessing levodopa-induced 
dyskinesia and bradykinesia in parkinsonian disorders 
[20,21]. 
The papers, which come slightly closer to our area 
of interest, study tremor frequency [22], measure 
rigidity of muscles [23], develop a quantitative method 
for 3D measurement of PD tremor, measure finger 
tapping contact force for quantitative diagnosis of PD, 
measure maximum pinching force to evaluate 
bradykinesia [24] and use single movement sensors for 
motor state detection and dyskinesia [25]. When looking 
at wearable sensors and systems for rehabilitation 
[26,27] we can find works which use motion analysis 
[28] and lateral belt worn accelerometer [29]. 
The field of healthcare Apps designed for helping 
PD patients has been very poorly researched. We could 
find publications which monitor well-being through 
Apps [30], performing non invasive blood pressure 
measurement with Android phones, but there are no peer 
reviewed papers which focus solely on PD. The only 
publication which promotes a smart phone application 
for the detection of tremor is available at [31].  This 
application does not administer PD drugs. 
 
3. The Background: PD and Drug 
Administration 
 
PD is a degenerative disorder of the central nervous 
system [32,33,34]. It is a chronic and progressive 
movement disorder, with symptoms which worsen over 
time. Most common motor signs of PD are tremor, 
rigidity, bradykinesia and postural instability.  Tremor 
usually occurs when a limb starts slightly shaking or 
oscillating with frequency 3-8 Hz [35]. Bradykinesia, or 
slow movement, is manifested when patients cannot 
perform fine tasks, they lose spontaneous movements 
and have difficulties with facial expressions [36]. 
Rigidity of muscles  is common, uncomfortable and 
painful [37].  When the PD progresses, symptoms 
become more prevalent and increase the disability of 
patients. 
PD is connected with death of nerve cells in 
substantia nigra, as a consequence of low production of 
dopamine and presence of Lewy bodies in remaining 
neurons. Lewy bodies are abnormal aggregates of 
protein that develop inside nerve cells and appear as 
spherical masses that displace other cell components 
[38].  Dopamine is a chemical that sends a message to 
the part of the brain for coordination and movement. 
When production of the dopamine drops below 80%, 
doctors talk about PD and with over time, dopamine 
doesn't stop decreasing [39].  
There is no cure for PD, but there are treatments 
which may alleviate the symptoms. The most frequently 
used is dopamine treatments [21], which replace 
missing dopamine with drugs such as Levodopa [40]. 
However, side effects are serious.  PD patients 
experience dyskinesia or involuntary movements, 
vomiting, dizziness and hallucinations [39,21].  The 
severity of dyskinesia is related to the level of PD drug 
administration. When PD progresses and side effects of 
taking Levodopa become more severe, doctors choose 
Deep Brain Stimulation [41].  
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3.1. The Problem with PD Drug Administration  
 
Optimization of PD treatment occurs when PD 
patients are administered the correct drug dosage, which 
suppress all symptoms, does not generate side effects 
and improve patient's wellbeing.  However, PD 
symptoms vary from patient to patient, they depend on 
patient’s activities and may change significantly 
throughout the day.  It is extremely difficult to predict 
the exact drug dosage for any PD patient.  They are often 
prescribed the same amount of drugs regardless of the 
current state of their symptoms [42]. This approach of 
suppressing PD  symptoms develops side effects quicker 
and the treatment becomes ineffective [43, 44].  The risk 
of dyskinesia is constant and depends on age, progress 
and severity of PD, dosage of drugs and the duration of 
Levodopa treatment.  
In order to extend dopamine treatment and reduce 
Levodopa’s side effects, many studies have been carried 
out towards the optimization of dosage of PD drugs. The 
amount of dopamine in the blood and PD state have 
negative correlation [22], which means the higher the 
state of PD, less dopamine is produced. In order to 
decrease PD’s symptoms and increase the level of 
dopamine, with correct drug administration, scientists 
tried two different approaches. One is based on 
mathematical models for the drug administration [45] 
and the other on the tracking the progress of PD 
symptoms through patient diaries. 
PD treatments based on patient diaries [46] initially 
showed promising results. They help, if a patient keeps 
his or her diary up to date. Doctors with diary's data may 
set up appropriate drug administration, change settings 
of the diaries [47,48] and may prescribe treatments 
which will not bring new disabilities in PD patient's life. 
However, the drawback of this approach is well known.  
Doctors often find incomplete and constantly missing 
data in patient diaries, which often makes the 
optimisation of drug treatments unfeasible [49].  
Administering drugs through predictions based on 
mathematical models, such as the Tauberan approach 
[18] or transfer function of second order [14], is based 
on the level of the concentration of the prescribed drug 
in the blood. However, PD symptoms vary from patient 
to patient and in this approach the specificity of PD 
symptoms, and ultimately personalisation of the drug 
administration are lost: all patients, with a particular 
level of the drug in the blood get the same dosage of 
medication, regardless of the severity of their PD 
symptoms. 
Currently, there are no solutions which personalise 
PD treatments.  In other words, there are no methods 
which can calculate the exact dosage for a particular PD 
patient at any time during the day.  
In this research, we aim to address both: how to 
perform PD drug administration more efficiently and 
how to personalise it according to a particular patient’s 
needs.  Therefore the proposal is to build a device which 
can measure the status of tremor and bradykinesia in a 
PD patient and generate a software program which can 
calculate the most appropriate PD drug dosage for the 
patient.  The solutions are in creating both: a device, 
equipped with sensors for the purpose of measuring PD 
symptoms and a software program, which manipulates 
sensor generated data in order to administer PD drugs.  
Our proposed solution is described in the following 
three sections.  
 
4. Prerequisite for Developing ParMes and 
ParMesApp  
 
We developed a ParMes device for measuring the 
severity of PD symptoms and ParMesApps Android 
App, which takes these measurements and calculates the 
best possible drug administration for a PD patient at the 
time when the measurements were taken. However, 
before we introduce both of them, we have to give a 
more detailed explanation on how the severity of PD 
symptoms can be estimated through ParMes and drug 
administration calculated, based on these estimates.  In 
other words, understanding the role of estimation of 
tremor and bradykinesia, helps in explaining the design 
principles for creating both ParMess and ParMessApp.   
 
4.1. Estimating Symptoms of PD 
 
The severity of tremor and bradykinesia can be 
estimated by measuring the applied force on the screen 
of a smart phone.  These two symptoms are visible on 
patient hands. 
The level of dopamine and tremor frequency are in 
negative correlation [22]. When a patient has a low 
dopamine level, the power of tremor will be higher.  The 
tremor's frequency occurs between 4-8 Hz. From 
obtained measures, which were taken for time period T 
and with sample frequency 256 Hz, our software 
solution (ParMesApp) should calculate the Power 
Spectrum Density (PSD) [50] for every frequency in 
band pass between 4-8 Hz, and normalize these values.  
Bradykinesia is measured with the help of applied 
pressure on the smart phone screen. From the obtained 
measurements, ParMesApp extracts reaction and 
movement time [24,14] and finds the highest value of 
applied pressure. Based on this value it calculates the: 
• Reaction time (Eq. (1)) is measured as the time 
when stimulus changes its state and measured 
signal will reach threshold point which is 10% of 
the measured sample with the highest value. 
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• Movement time (Eq. (2)) is measured as the time 
between the end of reaction time and when signal 
passes threshold 90% of the measured sample with 
highest value. 
If we have kn (nth sample), k10% (sample at 10% of 
maximum measured value), k90% (sample at 90% of 
maximum measured value), ∆t (time between two 
samples (∆ = 	1  ) and MMV - Maximum Measured 
Value, we can then define: 
 
tr	=	k10%	×	Δt	 (1) 
tm	=	(k90%	×	Δt)	-	tr	 (2) 
 
 
4.2. Calculating Drug Administration 
 
Even mathematics is used for the optimization of 
Levodopa treatment. In the pharmaceutical industry, 
producers of Levodopa developed the transfer function 
of the second order with drug administration as input. 
The output is the concentration Levodopa in blood, as 
given in [14]: 
() = 	

(1 + 1)(1 + 2) (3) 
 
However, K, T1, T2 values were determined by 
measuring medicine concentration in blood, several 
times after the patient with PD was administrated 
125mg of Levodopa.  Because the benefits pf taking 
Levodopa appears 10-15 minutes after its 
administration, the authors of [14]  added another 
variable in order to transfer function of the second order 
 where t is delay time.  Therefore formula (4) 
replaces formula (3).   
() = 	

(1 + 1)(1 + 2) (4) 
 
This equation models pharmacodynamics of the 
drug and describes the relation of administrated drug 
and effect of the drug, i.e. its amount in the blood. 
Doctors predict that 1500mg/L of the medicine in the 
blood is enough to suppress PD symptoms [52]. The 
level of medicine in the blood and the severity of the PD 
symptoms are in negative linear coloration and therefore 
we can calculate the difference between the current and 
desired amount of Levodopa in the blood. With this 
difference we can determine the required dosage of 
medicine, which won't harm the patient and will 
suppress symptoms. 
The cost function of medicine usage is a solution for 
reducing the amount of administered medicine, where   
presents dosage of the medicine and T time between two 
sessions of drug administrations [51]:  
 
(∆, ) = ! ×  +
"

 
(5) 
 
In order to reduce cost function F, we have to 
decrease  or increase T.  is an impulse which 
determines the relation between medicine 
administration and plasma level in the blood and it is a 
response of a transfer function second-order system with 
time leg. The amplitude of the impulse is the amount of 
prescribed medicine. If we know the first applied 
dosage, which initiated the system, amplitude of 
impulse  is the amount of the second dosage, the time 
response of the system will be:  
 
Y(t)	=	40.89×δ×(e-1.67(T-0.24)	–	e-18.57(T-0.27))	 (6) 
 
However, however successful formulas (3)-(6) are, 
they do not take into account that PD patients have 
changeable need for Levodopa administration 
throughout the day.  In other words we had to create a 
new formula because in our research we are interested 
in the amount of prescribe  at any time in the day. From 
equation (6) we extracted  and our final formula for 
administration of drug changes into; 
 
 =
/()
40.89 × (0.12(3.45) − 07.82(3.42)
 
(7) 
 
T is determined as time between previous and 
current administration of the drug, while Y(t) is the 
desired level of drug in the blood, based on the ratio of 
a symptom’s severity of a PD patient and a healthy 
person in the same measurement range.  
To summarise, we measure tremor and bradykinesia 
though the following: 
Tremor: if the affected limb oscillates with a 
frequency between 4-8 Hz we estimate the severity of 
tremor on average PSD  in bandpass from 4-8 Hz. The 
ratio is calculated from the average PSD of a PD patient 
and a healthy person and the desired level of drug in 
blood can be calculated as:  
 
Yt(t)	=	1500mg/L	×	(avrPSDPD	patient	/															
avrPSDhealty	person	)		
(8) 
 
 
Bradykinesia: the desired level of drug in the blood 
for patients with Bradykinesia is calculated upon 
reaction and movement time. We summarised reaction 
(Eq. 1) and movement (Eq. 2) time of a PD patient and 
a healthy person. Based on summation and ratio 
between summation, we calculated the desired level of 
drug as: 
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Yt(t)	=	1500mg/L	×		
((reaction+movement	time)PD	patient	
/(reaction+movement	time)healty	person	)  
(9) 
 
 
5. ParMes Device  
 
The main purpose of ParMes is to measure applied 
pressure of a human finger on its screen. 
For creating ParMes we had two options.  We could 
either attach ParMes on the back of a smart phone, in 
which case ParMes becomes a ”slave”, or create a 
completely new device which would not need a smart 
phone and would perform all: measurements, drug 
dosage calculation and interaction with a PD patient.  
Option 1 allows the use of parts and existing 
functionalities of smart phones and takes advantage of 
numerous software solutions, which exist on smart 
phones, in order to perform computations and ultimately 
deliver services expected by a PD patient. 
Option 2 would require more resources in order to 
deliver both: creation of hardware parts for ParMes 
(including screens) and software components.  This 
option can not offer as attractive operating environments 
for software development as our smart phones do.  
We chose option 1 and “the screen”, which we refer 
to is the screen of a smart phone. Our ParMes should 
behave as a slave device. When ParMes receives a 
request to measure a pressure caused by a PD patient’s 
finger, it starts measuring the applied force on the screen 
and sends the results of the measuring to the smart 
phone.  Therefore, smart phones manipulate the 
measurements of pressure caused by a human finger.  
There were two important issues which had to be 
addressed before ParMes was designed. 
Firstly, we had to take into account that the time 
between the beginning and the end of the measurement 
of a pressure, caused by a human finger, with ParMes is 
10 seconds.  In this period ParMes sends 256 samples of 
applied force per second. 
Secondly, we had to design hardware, which will 
meet special requirements.  It is supposed to be small 
and convenient to use. 
ParMes includes some basic analogue components 
such as an operational amplifier, switches and elements 
with resistive and capacitive properties and digital 
logical operators such as AND, OR, NOR, NAND, 
XOR, MUX and D-FlipFlops. They will naturally 
convert into electrical circuits.   Therefore ParMes has 
Analogue part, which measures voltage resulting after 
applying finger pressure and Digital part, which 
transforms these measurements into digital streams.  
Picture 1 shows the PCD hardware design of ParMes 
and Figure 2 shows how its device is attached to a smart 
phone. 
 
 
 
Figure 1. PCB hardware design of ParMes 
   
 
 
                
Figure 2. ParMes device attached on smart phone 
   
 
6. ParMesApp Android Application  
 
The design and development of the ParMesApp have 
three prerequisites. 
Firstly, an overall SA was needed for creating an 
environment where ParMesApp can reside and use 
sensor generated data by ParMes. The SA must also 
accommodate the functionality, which is expected to be 
delivered through the ParMesApp.  However, in this 
highly interactive and mobile environment, User 
Interfaces (UI) usually govern the logic of the 
manipulation of ParMesApp by a particular PD patient.  
Consequently, the functionalities depicted in the SA 
must be accompanied by a set of UI, which illustrate the 
way our ParMesApp works and the way a PD patient 
may manipulate it.  The UI for our ParMesApp is given 
in Figure 3.     
3493
  
Secondly, the abstract model of the SA, must be 
created through either UML diagrams or software 
patterns like Model-View-Controller (MVC) [52].  It 
should be layered and component based.  It should also 
deliver a generic solution for the manipulation of sensor 
generated data from ParMes and consequently absorb or 
accommodate all possible changes we may have in 
future when using ParMesApp.  The SA should also 
accommodate the way the calculations of Tremor/ 
Bradykinesia/PD drug administration are performed: we 
should be able to change the code for calculations and 
algorithms in future, if required.  
Thirdly, software components defined through the 
ParMesApp SA must be deployable within the Android 
Integrated Development Environment (IDE), such as 
Android Studio.  Therefore, abstract SA components 
become technology specific in order to have a 
successful deployment of ParMesApp.  It is assumed, 
particularly if MVC pattern is used, that SA strictly 
distinguishes between UI defined at the front end of 
ParMesApp and repositories of data, generated by 
sensors within ParMes, which are used for calculating 
drug administration for PD patients. 
Figure 3 shows UIs for ParMessApp. In the first UI, 
only two buttons are available: “TREMOR” and 
“BRADYKINESIA”. When a PD patient chooses which 
type of measurement he/she needs, the ParMesApp will 
lead the patient through the measurement procedure.  
When the measurement is completed, ParMesApp will 
show the results which are expected to be “Severity of 
PD symptoms” and “Recommended drug 
administration”.  The result screens are visible in the 
lower part of Figure 3.  
Figure 4. is a generic, layered and component based 
SA model for ParMesApp.  It uses the Model-View-
Controller (MVC) pattern. This model is deployable in 
many component based operating environments which 
are underpinned with component technologies [53,54]. 
Android IDE uses plug-ins which deploy the 
architectural solution from Figure 4. within the Android 
Studio.  
In Figure 4, UIs, which are illustrated in Figure 3, 
are in boxes with yellow borders.  Computation which 
control the ParMesApp are in red, calculations of drug 
dosage (named FFT and R&M) are in green and data 
repositories are in blue.  A strict division between UI, 
computations and data is essential. This makes the SA 
solution from Figure 4 reusable in any other IDE. 
ParMesApp may have two different types of 
repositories.  One should be a pool of sensor-generated 
data (SGD) by ParMes, which contains measurement of 
a PD patient's finger pressure.  This data does not have 
to be persistent.  SGD belong to a particular moment of 
measurement and cannot be used again for a new 
calculation of the drug dosage.  The other type of data is 
a traditional database repository, i.e. persistent data, 
which may store demographic and clinical data relevant 
to a particular PD patient.  The development of the latter 
is outside the scope of this paper.  However, access to 
persistent data must be guaranteed through the SA 
offered for ParMesApp.  In other words, the SA model 
gives provision for accessing any persistent repository 
of structured data, if needed.  
 
 
 
Figure 3. User interfaces in ParMesApp 
 
It is important to note that all computations in Figure 
4, which need data, will be performed after retrieving 
relevant data.  This applies to all types of data: it can 
either be sensor generated data from ParMes or 
persistently stored data, about PD patients. This puts 
forward the main characteristics of this SA solution: all 
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components shown in Figure 4 might be located on 
different nodes of any computer network. The solution 
consequently allows data sharing in their repositories 
and makes provisions for flexibility in case we change 
the way we digitalize analogue signals of ParMes, or 
change the way we calculate recommended drug 
dosage.  This is particularly important if advances in 
research on treatments of PD would make the change 
necessary. 
 
 
 
 
Figure 4. Software Architecture for ParMesApp 
 
Finally, sensor generated data may not be important 
to store and keep it as historical data, i.e. it might not be 
advisable to make it persistent.  What is important here 
is to make decision on the PD drug administration 
possibly persistent and encourage frequent 
measurements of Tremor and Bradykinesia in order to 
minimize errors when administering PD drugs.  
 
7. Conclusions 
 
In this paper we demonstrate that it is feasible to 
utilise modern hardware/software technologies for 
creating dynamic cyber-physical environments where 
PD patients are able to measure the severity of their 
symptoms, at any time throughout the day, and have the 
PD drugs administered according to these 
measurements.  ParMes and ParMesApp have been 
developed as prototypes, but their commercialisation is 
a small step away from the results of this research. 
There are two important outcomes from this 
research. 
The evaluation of ParMes and ParmessApp has 
revealed that the idea of creating a device, attaching it 
to a smart phone and running an App on the phone, in 
order to measure the rigidity of PD patient’s muscles, is 
reusable in other healthcare domains. This was not 
expected.  Both solutions ParMes and ParmessApp  will 
require no major changes if we wish to use both in 
different environments and for different purposes. 
However, the evaluation prompted another 
important aspect of ParMes, which should be debated.  
While testing ParMes and analysing Apps available on 
our smart phones, it became obvious that smart phones 
are becoming more efficient in managing our wellbeing 
and more popular in the delivery of healthcare, then 
various gadgets specially designed for healthcare. 
Therefore we had to ask questions: Was our PaerMes 
necessary? Would we achieve the same result if we used 
either Android or iOS devices and run ParMessApp on 
them? 
We debate these two outcomes in section 7.1 and 
7.2. 
 
7.1. Evaluation 
 
It is important to note that connecting ParMes, 
equipped with sensors which generate data, with an 
Android App, which is built upon a specific SA style 
from Figure 4, answers many questions we may have 
when evaluating the results of this research.  
Firstly, the generic SA style from Figure 4, based on 
MVC pattern, secures the flexibility of the ParMesApp 
because its computational components are separated 
from persistence / data repositories and UI.  Any future 
changes we may have when estimating tremor and 
bradykinesia and calculating the recommended drug 
dosage can be easily accommodated within the 
ParMesApp, without affecting most of its software 
components. 
Secondly, if we needed readings of anyone’s finger 
pressure on a smart phone screen for any other condition 
or illness, the SA of ParMesApp provides a clearly 
defined UI and repository components which can be 
developed for drug administration not related to PD.  In 
other words, we can use the model defined in Figure 4 
for drug administration of any other condition which 
may depend on the measurements of someone’s finger 
pressures. 
Thirdly, the SA from Figure 4 is a sound way of 
creating Apps if we wish them to be robust and reliable 
when they are run by patients.  If the SA style defined 
in Figure 4 is deployable within an Android Studio, as 
an IDE, then we should be able to promote this 
particular way of constructing software for pervasive 
healthcare. In other words, any future App which 
depends on the manipulation of sensor generated data, 
should exploit the power of Figure 4 before developers 
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start coding in Android or any other mobile /wireless 
operating environments. 
Finally, Our ParMesApp delivers advice on PD drug 
administration at the moment when the measurement of 
PD symptoms are taken. It personalizes drug 
administration and makes it precise to fit the needs of a 
patient, at the moment when the patient decides. 
ParMesApp can run many times per day, when PD 
symptoms change. This might be the most important 
outcome of this research.  
 
7.2. ParMes in Testing  
 
Throughout the development process of ParMes and 
ParMesApp we were constantly aware that our idea of 
creating a separate mobile device ParMes for the 
measurements of the finger pressure of a PD patient may 
lead us towards a completely different debate on the 
efficiency of having two mobile devices. 
Our ParMes is attached to a smart phone and in 
numerous testing, this synergy worked very well.  We 
proved that it was not difficult to design and develop 
ParMes, but it was extremely difficult to place the 
computations for drug administration on it.  We needed 
a smart phone and its operating environment, if we 
wished to manipulate sensor-generated data. Smart 
phones give much more power and opportunities for 
creating intelligent software solutions, compared to any 
device (gadet) equipped with sensors.  
Consequently having a new developed gadget 
ParMes as a “slave” to any Android smart phone, in 
order to enable decision making on PD drug 
administration, was a necessity.  Patients do want to run 
Apps on their own smart phones and therefore there was 
no other way but to use ParMes as a slave.  We could 
not make conclusions on the readiness of smart phone 
technologies to replace our ParMes, but the 
computational intelligence we could create on ParMes 
could not be compared with powerful Android, which is 
present almost everywhere and across environments 
where we need to run Apps.   
 
7.3. Future Work  
 
Considering our debate in sections 7.1. and 7.2, more 
research is needed to investigate how smart phones 
might replace ParMes in future.  Computationally 
powerful Android environments can carry sophisticated 
calculations, which could question the existence of 
numerous gadgets we buy off the shelf. These gadgets 
assist in our everyday lives, but do not have enough of 
their own power in order to create intelligent software 
solutions for users. 
It has to be debated if the future of pervasive 
healthcare is in 
(a) creating more mobile devices equipped with 
sensors, and add more computational power to them or 
(b) increasing the use of smart phones, instead of 
developing more gadgets equipped with sensors. Smart 
phones provide a window of opportunities because they 
live in Android (or any other similar) operational 
environments and can create naturally more intelligent 
software solutions for the delivery of healthcare. 
Our ParMesApp on an Android phone can 
manipulate sensor-generated data and perform 
relatively complicated calculations, but ParMes alone 
can not do it. It remains to be seen which way gadget 
manufacturers and App developers will go. Whatever 
the future of ParMes would be, the reusability of SA 
form Figure 4 guarantees successful creation of Apps in 
any operating environment, if relevant sensor generated 
data is supplied. 
 
10. References  
 
[1] “Recent Developments in Personalized Medicine”, by 
The Royal Society, London, UK , 2015, available at 
https://royalsociety.org/~/media/policy/Publications/2015/per
sonalised-medicine-report.pdf  
 
[2] O. Hamdi, M. A. Chalouf, and D. Ouattara, “eHealth : 
Survey on research projects , comparative study of 
telemonitoring architectures and main issues,” Netw. 
Comput. Appl., vol. 46, pp. 100–112, 2014. 
 
[3] J. P. Harrison and A. Lee, “The Role of E-Health in the 
Changing Health Care,” Nurs. Econ., vol. 24, no. 6, pp. 283–
288, 2006. 
 
[4] Y. Akematsu and M. Tsuji, “Economic Effect of eHealth : 
Focusing on the Reduction of Days Spent for Treatment,” 
IEEE, pp. 14–20, 2009. 
 
[5] G. Graschev, S. Rakowsky, T.A. Roelofs, P.M. Schlag, 
“New Medicla Technologies of Future”, in Proceedings of 
the Internaitonal Conference on Digital Technologies (DT), 
IEEE, pp 84-89, 2013. 
 
[6] C. Vandelanotte, C. E. Short, M. M. Andre, M. Hingle, N. 
Nathan, B. Hons, S. L. Williams, M. L. Lopez, S. Parekh, 
and C. A. Maher, “Report Past, Present , and Future of 
eHealth and mHealth Research to Improve Physical Activity 
and Dietary Behaviors,” Journal Nutrition, Education and 
Behaviour, vol. 48, no. 3,  pp. 219-228, March 2016. 
 
[7] E. Reilent, I. Loobas, R. Pahtma, A. Kuusik, “Medical 
and Contetx Data Acquisition System for Paitent Home 
Monitoring”, in Proceedings of the 12th Biennial Baltic 
Eøectronics Conference (BEC 2010), Tallin, Esotnia, pp. 
269-272, 2011. 
 
[8] X.-F. Teng, Y.-T. Zhang, C. C. Y. Poon, and P. Bonato, 
“Wearable Medical Systems for p-Health,” IEEE Review on. 
Biomedical Engineering., vol. 1, pp. 62 – 74, 2008. 
3496
  
 
[9] A. Lymberis, “Smart wearable systems for personalised 
health management: Current R&D and future challenges,” 
Proc. 25th Ann. Int. Conf. IEEE EMBS, vol. 4, pp. 3716–
3719, 2003. 
 
[10] G. TrÃster, “The agenda of wearable healthcare,” IMIA 
Year Book of Medical Informatics 2005 Ubiquitous Health. 
Care Systems (Haux R, Kulikowski C, editors) pp. 125–138, 
2004. 
 
[11] J. E. Mezzich, “Psychiatry for the Person: articulating 
medicine's science and humanism” World Psychiatry, vol. 6, 
no. 2, pp. 65–67, 2007. 
 
[12] P.B. Shull, D. Damian “Haptic wearables as sensory 
Replacement, snesory augmentation and trainer - a review”, 
in Journal of NeuroEngineering and Rehabilitaiton, 12(59), 
2015. 
 
[13] R. Shojanoori, R. Juric, R., M. Lohi, “Computationally 
Significant Semantics in Pervasive Healthcare”, Journal of 
Integrated Design and Process Science, IOS Press, Volume 
16, Number 1 – 2012, pp 43-62. 2012.  
 
[14] S.S. Hacisalihzade, M. Mansour, and C. Albani, 
“Optimization of symptomatic therapy in Parkinson’s 
disease.,” IEEE Trans. Biomed. Eng., vol. 36, no. 3, pp. 363–
372, 1989. 
 
[15] R. Prasad, S.S. Babu, N. Siddalah, K.S. Rao “A Review 
of Techniques for Diagnosing and Monitoring Paitents with 
Parkinson Disease”, in Journal of Biosensors and 
Bioelectronics, Volume 7, Number 1, 2016. 
 
[16] M. Sarestonemi, J. Iinati, N. Keranen,  T. Jamsa, J 
Partala, T. Seppanen, J. Reponen, J. “Receiver Prformance 
on IEEE 802.15.6 based WBAN for Monitoring Parkinson 
Disease”, in Proceedings of the  8th International Symposium 
on Medical Information and Communication Technology 
(ISMICT), 2014. 
 
[17] Tsanas, A., Little, M.A., McSharry, P., Ramig, L. 
“Accurate telemonitoring of Parkinson disease progression 
by non-invasive speech tests”, IEEE Transacitons on 
Biomedical Engineering, 2010, 57(4) 
 
[18] S. S. Hacisalihzade, M. F. Senning, and R. Strotz, 
“Optimization of Drug Administration by a Tauberan 
Approach,” IEEE Transacitons on Biomedical Engineering, 
vol. 34, issue 4, pp. 430–436, 1987. 
 
[19] M. G. Tsipourasa, A. T. Tzallasa, G. Rigasa, S. Tsoulib, 
and Dimitrios I. Fotiadisa Spiros Konitsiotis, “An automated 
methodology for levodopa-induced dyskinesia: Assessment 
based on gyroscope and accelerometer signals,” Artif. Intell. 
Med., vol. 55, no. 2, pp. 127–135, 2012. 
 
[20] G. Pal and C. G. Goetz, “Assessing bradykinesia in 
Parkinsonian disorders,” Front. Neurol., vol. 4, no. June, pp. 
1–5, 2013. 
   
[21] B. Thanvi, N. Lo, and T. Robinson, “Levodopa-induced 
dyskinesia in Parkinson’s disease: clinical features, 
pathogenesis, prevention and treatment,” Postgrad. Med. J., 
vol. 83, no. 980, pp. 384–388, 2007. 
 
[22] Y. Matsumoto, K. Shindo, M. Sakakibara, M. Tamura, 
and I. Fukumoto, “Study on the 8Hz tremor frequency related 
to dopamine level in Parkinsonian patients,” Proceedings of 
the Annual. Inernational Conference IEEE Eng. Med. Biol., 
vol. 4, pp. 1771–1772, 1996. 
 
[23]  A. Prochazka, D. J. Bennett, M. J. Stephens, S. K. 
Patrick, R. Sears-duru, T. Roberts, and J. H. Jhamandas, 
“Measurement of Rigidity in Parkinson ’ s Disease,” Mov. 
Disord. Soc., vol. 12, no. 1, pp. 24–32, 1997. 
 
[24] T. Touge, K. Tsutsui, K. Kume, K. Ikeda, K. Deguchi, 
Y. Nakamura, H. Sciences, and S. Hospital, “Measuring the 
Maximum Pinching Force is a Good Procedure to Evaluate 
Bradykinesia in Patients with Parkinson ’ s Disease,” 
Complex Med. Eng. (CME), 2011, pp. 192–194, 2013. 
 
[25] Sama, A., Perez-Lopez, C., Romagosa, J. Rodriguez-
Martin, D., Catala, A., Cebastany, J., Perez-Martinez, D.A., 
Rodriguez-Molinero, A. “Dyskinesia and motor state 
detection in Parkinson's disease patients with a single 
movement sensor”,  Porceedings of the 34th Annual 
Conference of the IEEE EBMS, pp 1194-1197, 2012. 
 
[26] S. Patel, H. Park, P. Bonato, L. Chan, and M. Rodgers, 
“A review of wearable sensors and systems with application 
in rehabilitation,” in Journal of Neuroengineering 
Rehabilitaions, Vol. 9, no. 21, pp. 1–17, 2012. 
  
[27] P. Bonato “Wearable Sensors and Systems”, in IEEE 
Engineering in Medicine and Biology Magazine, vol. 29, no. 
3, pp. 25-36, 2010. 
 
[28] G. Lo, A.R. Suresh, L. Stocco, S. Gonzales-Valenzuela, 
V.C.M. Leung, “A Wireless Sensor System fo rmOtion 
Analysis of Parkinson's Disease Paitents”, delivered at 
PerCom workshop in 2011 as work in Progress. 
 
[29] Sayeed, T., Sama, A., Catala, A., Cebastany, J. 
“Comparative and adaptation of step detection and step 
length estimators to lateral belt worn accelerometer”, in IEEE 
HEALTHCOM, The 1st internaitonal Workshop on Service 
Science for e-Heaølth, 2013. 
 
[30]  E. Lane, M. T. Willams, T. Olds, and C. Maher, “An 
internet-based physical activity intervention for adolescents 
with cerebral palsy: a randomized controlled trial.,” Dev Med 
Child Neurol, vol. 52, no. 5, pp. 448–55, 2010. 
 
[31] V. Parra, P. Milano, G. Figueras, M. Huerta, I. Member, 
A. Marzinotto, R. Gonzalez, and R. Alvizu, “A Smartphone 
Application for Parkinson Tremor Detection”, VI Latin 
American Congress on Biomedical Engineering CLAIB 
2014, Paraná, Argentina, Volume 49 of the series IFMBE 
Proceedings pp 785-788, 2015. 
3497
  
 
[32] J. Parkinson, “An essay on the shaking palsy. 1817.,” J. 
Neuropsychiatry Clin. Neurosci., vol. 14, no. 2, pp. 223–236; 
discussion 222, 1817. 
  
[33] S. D. Kim, N. E. Allen, C. G. Canning, and V. S. C. 
Fung, “Postural instability in patients with Parkinson’s 
Disease: Epidemiology, pathophysiology and management,” 
CNS Drugs, vol. 27, no. 2, pp. 97–112, 2013. 
 
[34] B. Thomas and M. F. Beal, “Molecular insights into 
Parkinson's disease", F1000 Medical Report, vol. 16, no. 2, 
pp. 183–194, 2007. 
 
[35]  T. R. Mhyre, J. T. Boyd, R. W. Hamill, and K. A. 
Maguire-Zeiss, “Protein Aggregation and Fibrillogenesis in 
Cerebral and Systemic Amyloid Disease,” Subcell. Biochem., 
vol. 65, pp. 389–455, 2012. 
 
[36] J.C. Berardelli, J. C. Rothwell, P. D. Thompson, and M. 
Hallett, “Pathophysiology of bradykinesia in Parkinson’s 
disease.,” Brain, vol. 124, no. Pt 11, pp. 2131–2146, 2001. 
 
[37] B. Sepehri, G. A. Shahidi, A. Esteki, and M. Moinodin, 
“Measurement of rigidity in elbow joint an objective method 
for evaluation of rigidity involved diseases,” ICBPE 2006 - 
Proc. 2006 Int. Conf. Biomed. Pharm. Eng., p. a – f, 2006. 
 
[38] Dickson, Feany, Yen, Mattiace, and Davies, 
“Cytoskeletal pathology in non-Alzheimer degenerative 
dementia: new lesions in diffuse Lewy body disease, Pick’s 
disease, and corticobasal degeneration,” J Neural Transm 
Suppl., vol. 47, pp. 31–46, 1996. 
 
[39] M. M. Goldenberg, “Medical management of 
Parkinson’s disease.,” P T Journal, vol. 33, no. 10, pp. 590–
606, 2008. 
 
[40] S. L. Smith, M. A. Lones, M. Bedder, J. E. Alty, J. 
Cosgrove, R. J. Maguire, M. E. Pownall, D. Ivanoiu, C. Lyle, 
A. Cording, and C. J. H. Elliott, “Computational approaches 
for understanding the diagnosis and treatment of Parkinson’s 
disease,” IET Syst. Biol., vol. 9, pp. 1–8, 2015. 
 
[41]  S. Patel, T. Hester, R. Hughes, N. Huggins, D. 
Standaert, A. Flaherty, and P. Bonato, “Using wearable 
sensors to enhance DBS parameter adjustment for 
Parkinson’s disease patients through measures of motor 
response,” Proc. 3rd IEEE-EMBS Int. Summer Sch. Symp. 
Med. Devices Biosensors, ISSS-MDBS 2006, pp. 141–144, 
2006' 
 
[42] J. Jankovic, “Current approaches to the treatment of 
Parkinson ’ s disease,” Neuropsychiatric Disease and 
Treatment, vol. 4, no. 4, pp. 743–757, 2008. 
 
[43] C. S. Okereke, L. Kirby, D. Kumar, E. I. Cullen, R. D. 
Pratt, and W. A. Hahne, “Concurrent administration of 
donepezil HCl and levodopa / carbidopa in patients with 
Parkinson ’ s disease : assessment of pharmacokinetic 
changes and safety following multiple oral doses,” Br. J. 
Clin. Pharmacol., vol. 41, pp. 41–49, 2004 
 
[44] M. Yokochi, “Reevaluation of levodopa therapy for the 
treatment of advanced Parkinson ’ s disease,” Park. Realt. 
Disord., vol. 15, pp. S25–S30, 2009. 
 
[45] J. Best, G. Oakley, M. Reed, and H. F. Nijhout, 
“Mathematical models: interactions between serotonin and 
dopamine in Parkinson’s Disease.,” Etiol. Pathophysiol. 
Park. Dis., pp. 405–420, 2011. 
 
[46] N. Saito, T. Yamamoto, Y. Sugiura, S. Shimizu, and M. 
Shimizu, “Lifecorder: a new device for the long-term 
monitoring of motor activities for Parkinson’s disease.,” 
Intern. Med., vol. 43, no. 8, pp. 685–692, 2004. 
 
[47] J. Schneider, D. Novak, and R. Jech, “Optimization of 
Parkinson Disease treatment combining anti-Parkinson drugs 
and deep brain stimulation using patient diaries.,” Conf. 
Proc.  ... Annu. Int. Conf. IEEE Eng. Med. Biol. Soc. IEEE 
Eng. Med. Biol. Soc. Annu. Conf., vol. 2015, pp. 3444–7, 
2015. 
 
[48] O. Rascol, D. J. Brooks, E. Melamed, W. Oertel, W. 
Poewe, F. Stocchi, and E. Tolosa, “Rasagiline as an adjunct 
to levodopa in patients with Parkinson’s disease and motor 
fluctuations (LARGO, Lasting effect in Adjunct therapy with 
Rasagiline Given Once daily, study): A randomised, double-
blind, parallel-group trial,” Lancet, vol. 365, no. 9463, pp. 
947–954, 2005. 
 
[49] J. Reimer, M. Grabowski, O. Lindvall, and P. Hagell, 
“Use and interpretation of on/off diaries in Parkinson’s 
disease,” J Neurol Neurosurg Psychiatry, vol. 75, pp. 396–
400, 2004. 
 
[50] T. Heida, E. C. Wentink, and E. Marani, “Power spectral 
density analysis of physiological, rest and action tremor in 
Parkinson’s disease patients treated with deep brain 
stimulation.,” J. Neuroeng. Rehabil., vol. 10, no. 1, p. 70, 
2013. 
 
[51] M. Haeri, Y. Sarbaz, and S. Gharibzadeh, “Modeling the 
Parkinson’s tremor and its treatments,” J. Theor. Biol., vol. 
236, no. 3, pp. 311–322, 2005. 
 
[52] E. Gamma, R. Helm, R. Johnson, J. Vlissides “Design 
Patterns: Elements of Reusable Object-Oriented Software, 
Addison Wesley 1995. 
 
[53] N. E. T. Framework, , “Overview of the . NET 
Framework,” pp. 1–4, 2016. 
 
[54] E. J. Developer and G. Release, “Oracle9 i AS 
Containers for J2EE,” vol. 2, no. August, 2002.   
 
 
       
3498
